Perceptive Advisors’s Dyne Therapeutics DYN Stock Holding History

Perceptive Advisors’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$59.7M	Sell	2,689,235 -1,979,604	-42%	-$36.8M	0.9%	27
2026 Q1	$84.6M	Buy	4,668,839 +1,189,895	+34%	+$20.5M	1.65%	20
2025 Q4	$68M	Buy	3,478,944 +2,938,500	+544%	+$55.6M	1.21%	26
2025 Q3	$6.84M	Sell	540,444 -1,706,946	-76%	-$19.5M	0.2%	68
2025 Q2	$21.4M	Sell	2,247,390 -66,013	-3%	-$727K	0.79%	34
2025 Q1	$24.2M	Buy	2,313,403 +1,770,126	+326%	+$25.3M	0.85%	32
2024 Q4	$12.8M	Sell	543,277 -174,867	-24%	-$5.17M	0.35%	52
2024 Q3	$25.8M	Buy	+718,144	New	+$28.6M	0.55%	46
2021 Q1	–	Sell	-400,000	Closed	-$8.4M	–	147
2020 Q4	$8.4M	Hold	400,000	–	–	0.09%	111
2020 Q3	$8.08M	Buy	+400,000	New	+$8.78M	0.12%	96

Other funds holding DYN

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Perceptive Advisors's DYN Position: Q2 2026 in Review

Perceptive Advisors reduced its Dyne Therapeutics (DYN) stake by 42% in Q2 2026, selling an estimated $36.8M and leaving 2,689,235 shares worth $59.7M. The position accounts for 0.9% of the portfolio, ranked #27.

Perceptive Advisors first reported a position in DYN in Q3 2020 and has held it in 10 quarters since. The position peaked at $84.6M in Q1 2026. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

Perceptive Advisors held 2,689,235 shares of Dyne Therapeutics worth $59.7M as of Q2 2026.
Perceptive Advisors sold 1,979,604 Dyne Therapeutics shares in Q2 2026, an estimated $36.8M.
Dyne Therapeutics made up 0.9% of Perceptive Advisors's portfolio in Q2 2026, its #27 holding.
Perceptive Advisors first reported a position in Dyne Therapeutics in Q3 2020 and has held it in 10 quarters since.
Perceptive Advisors's Dyne Therapeutics position peaked at $84.6M in Q1 2026.
245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Perceptive Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.